An imaging agent (panitumumab-IRDye800) to find head and neck cancer during surgery

You may qualify if

• Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck
• Diagnosis of any T stage, any subsite within the head and neck that are scheduled to undergo surgical resection. Patients with recurrent disease or a new primary will be allowed.
• Planned standard of care surgery with curative intent for squamous cell carcinoma
• Male or female patients age ≥ 18 years
• Have life expectancy of more than 12 weeks
• Karnofsky performance status of at least 70% or ECOG/Zubrod level 1
• Have acceptable hematologic status, coagulation status, kidney function, and liver function including the following clinical results:; Hemoglobin ≥ 9 gm/dL; Absolute Neutrophil Count ≥ 1500; White Blood Cell count > 3000/mm3; Platelet count ≥ 100,000/mm3; Serum creatinine ≤ 1.5 times upper reference range

You can't join if

• Received an investigational drug within 30 days prior to first dose of panitumumab-IRDye800
• Had within 6 months prior to enrollment: MI, CVA, or uncontrolled CHF
• History of infusion reactions to any monoclonal antibody therapies
• Women who are pregnant or breast-feeding
• Evidence of QT prolongation on pretreatment ECG (greater than 440 ms in males or greater than 450 ms in females)
• Magnesium or potassium lower than the normal institutional values
• Patients receiving Class IA (quinidine, procanamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents
• Patients with a history or evidence of interstitial pneumonitis or pulmonary fibrosis
• TSH > 13 micro International Units/mL